Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Tuesday, August 6, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes.

During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2024.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com

Staff

Recent Posts

GaraHerb Supplement Facts, Ingredient Label Details, and Product Disclosures: A 2026 Informational Overview of Male Enhancement Supplement Options

Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…

1 day ago

Cannabix Technologies announces Non-Brokered LIFE Private Placement

  NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…

1 day ago

LuminEye Nano-Drops Product Information Updated as Consumer Interest in Eye Health Supplement Options and Vision Support Alternatives Grows in 2026

An informational overview examining category context, publicly available product disclosures, and what consumers often consider…

1 day ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”)…

1 day ago

Laughland Teeth Whitening Kit: Ingredients, Disclosures, and What Consumers Are Researching in 2026

A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product…

1 day ago